Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792191 | 0.79 | CFTR (0.52) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL6631615 | 0.79 | CFTR (0.52) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL9906896 | 0.78 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1753695 | 0.78 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL18513564 | 0.78 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1515348 | 0.77 | — | — | |
| SCHEMBL4198760 | 0.76 | CFTR (0.64) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL6205478 | 0.76 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL8355124 | 0.76 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL12714386 | 0.76 | SMN1; SMN2 (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102718727-A | Arylurea derivative with dual GK/PPAR agonist activities | INST MATERIA MEDICA CAMS | 2012-10-10 | — | — | CN | claimed |
| CN-102718703-A | Dimethyl-containing arylurea derivative with dual GK/PPAR agonist activities | INST MATERIA MEDICA CAMS | 2012-10-10 | — | — | CN | claimed |
| CN-102718703-B | GK and PPAR double excitation activity containing dimethylated aryl urea derivant | 中国医学科学院药物研究所 | 2016-09-14 | — | — | CN | disclosed |
| CN-102718727-B | The aryl urea derivative of GK and PPAR double excitation activity | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-04-20 | — | — | CN | disclosed |
| CN-102718727-A | Arylurea derivative with dual GK/PPAR agonist activities | INST MATERIA MEDICA CAMS | 2012-10-10 | — | — | CN | disclosed |
| CN-102718703-A | Dimethyl-containing arylurea derivative with dual GK/PPAR agonist activities | INST MATERIA MEDICA CAMS | 2012-10-10 | — | — | CN | disclosed |
| US-6737429-B2 | TREATMENT OF HIV MEDIATED DISEASES. | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | CFTR 1510/4885SLC6A2 2830/4885SLC6A4 1811/4885 |
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | CFTR 2986/4885SLC6A2 4843/4885SLC6A4 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.